Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -2.08 is 122% below its 5-year average of -0.94, near the low end of its 5-year range (-2.08–1.46).
5.58% below its 12-month average of -1.97.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.41.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 20 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T15:55:32.409Z. Historical observations retain their original dates. Historical series through 2023-02-28.
EARNINGS PER SHARE (EPS)
-2.08
EARNINGS PER SHARE (EPS) AVG TTM
-1.97
EARNINGS PER SHARE (EPS) AVG 3Y
-1.74
EARNINGS PER SHARE (EPS) AVG 5Y
-0.94
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-5.58%
CURRENT VS 3Y AVG
-19.54%
CURRENT VS 5Y AVG
-121.67%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Atea Pharmaceuticals, Inc.
Market Cap
$410.94M
Earnings Per Share (EPS)
-2.08
TTM Avg
-1.97
3Y Avg
-1.74
5Y Avg
-0.94
Market Cap
$411.32M
Earnings Per Share (EPS)
-1.19
TTM Avg
-2.69
3Y Avg
-2.49
5Y Avg
-2.21
Market Cap
$409.27M
Earnings Per Share (EPS)
-1.71
TTM Avg
-1.36
3Y Avg
-1.12
5Y Avg
-1.12
Market Cap
$408.73M
Earnings Per Share (EPS)
-1.36
TTM Avg
-1.81
3Y Avg
-2.62
5Y Avg
-2.62
Market Cap
$415.36M
Earnings Per Share (EPS)
-5.51
TTM Avg
-4.26
3Y Avg
-3.91
5Y Avg
-2.87
Market Cap
$416.59M
Earnings Per Share (EPS)
-4.63
TTM Avg
-6.16
3Y Avg
-6.16
5Y Avg
-6.16
Market Cap
$422.75M
Earnings Per Share (EPS)
-0.84
TTM Avg
-3.40
3Y Avg
-3.01
5Y Avg
-2.22
Market Cap
$397.84M
Earnings Per Share (EPS)
-5.18
TTM Avg
-2.77
3Y Avg
-1.90
5Y Avg
-1.90
Market Cap
$396.61M
Earnings Per Share (EPS)
-3.79
TTM Avg
-4.17
3Y Avg
-5.22
5Y Avg
-3.47
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | $410.94M | -2.08 | -1.97 | -1.74 | -0.94 |
| Myriad Genetics, Inc. (MYGN)vs › | $411.32M | -1.19 | -2.69 | -2.49 | -2.21 |
| Shoulder Innovations, Inc. (SI)vs › | $409.27M | -1.71 | -1.36 | -1.12 | -1.12 |
| Carlsmed, Inc. (CARL)vs › | $408.73M | -1.36 | -1.81 | -2.62 | -2.62 |
| Neurogene Inc. (NGNE)vs › | $415.36M | -5.51 | -4.26 | -3.91 | -2.87 |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $416.59M | -4.63 | -6.16 | -6.16 | -6.16 |
| Prothena Corporation plc (PRTA)vs › | $422.75M | -0.84 | -3.40 | -3.01 | -2.22 |
| MapLight Therapeutics, Inc. (MPLT)vs › | $397.84M | -5.18 | -2.77 | -1.90 | -1.90 |
| REGENXBIO Inc. (RGNX)vs › | $396.61M | -3.79 | -4.17 | -5.22 | -3.47 |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $386.05M | -2.94 | -3.49 | -2.70 | -2.28 |
Trailing EPS (TTM)
$-2.08
Forward EPS (Est.)
$-1.98
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.94 |
| 2024-12-31 | -2.00 |
| 2023-12-31 | -1.63 |
| 2022-12-31 | -1.39 |
| 2021-12-31 | 1.46 |
| 2020-12-31 | -0.13 |
| 2019-12-31 | -0.16 |
| 2018-12-31 | -0.90 |
